Avtal | $24,000,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Fuse Biotherapeutics
United States
- Los Angeles, CA
- 30/11/2021
- Seed
- $9,500,000
At FuseBio, we are dedicated to developing transformative immune modulating therapeutics for patients with cancers. Our therapeutic approach integrates the multiple steps of an immune response in a rational manner such that potent responses to danger are targeted without sacrificing natural breaks in the system that spare healthy tissues.
- Industry Biotechnology
- Website https://www.fusebiotx.com/
- LinkedIn https://www.linkedin.com/company/fusebiotx/
Related People
Paul Y. Song, MDCo Founder
United States -
Los Angeles Metropolitan Area
Board Certified Radiation Oncologist. Experienced Biotech Executive and Chief Medical Officer with a demonstrated history of working in the biotechnology and medical industry. Skilled in Management, Translational Medicine, Clinical Trials, Regulatory Affairs, Medical Devices, Diagnostics, Oncology, Immunology, Governmental Affairs, Therapeutic Development, and Healthcare Policy. Strong healthcare services professional graduated from University of Chicago.
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)